IL2 and neoplasm: It involves the extraction of lymphocytes directly from a patient's tumor and their expansion ex vivo in a culture enriched with IL-2, anti-CD3 monoclonal antibodies, and allogeneic feeder cells before their eventual re-infusion for treatment purposes.